arrow
I

Igor Bondarenko

gustave roussy
H指数:85
被引数:5.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adjuvant alectinib versus chemotherapy in resected ALK- positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial

辅助阿来替尼与化疗在切除后的ALK阳性非小细胞肺癌(ALINA):一项随机、开放标签、III期试验的健康相关生活质量与安全性结果

2026-08-010
OAAI
Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial

ALK阳性早期非小细胞肺癌切除患者的疾病特征和治疗结局:来自随机ALINA试验

2026-04-010
PRE
Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy

EMPOWER-Lung 1研究中,接受cemiplimab治疗与化疗的晚期非小细胞肺癌患者报告结局的回顾

Cancer
IF5.1
2026-03-110
OAAI
Plain language summary of the ALINA study results: alectinib compared with chemotherapy after surgery in people with ALK-positive non-small cell lung cancer

ALINA研究结果的大众语言摘要:alectinib与化疗相比,在ALK阳性非小细胞肺癌患者术后的应用

2025-12-310
PRE
Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study

瑞格非尼单抗与安慰剂联合铂类化疗在一线非鳞状或鳞状转移性非小细胞肺癌患者中的比较(POD1UM-304):一项三期、多区域、安慰剂对照、双盲、随机研究

2025-09-190
PRE
Durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: outcomes in age, sex, and platinum subgroups from the phase 3 CASPIAN study

度伐利尤单抗联合铂类-依托泊苷治疗广泛期小细胞肺癌:CASPIAN III期研究中不同年龄、性别和铂类亚组的结果

2025-08-050
OAAI
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial

卡博替尼联合阿替利珠单抗在转移性前列腺癌中的研究(CONTACT-02):一项III期、开放标签、随机试验的最终分析

2025-06-130
PRE
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1

Cemiplimab单药治疗PD-L1表达≥50%的晚期NSCLC患者的一线治疗:EMPOWER-Lung 1研究五年结局

2025-03-190
OAAI
POD1UM-304: Phase III study of retifanlimab plus platinum-based chemotherapy (Chemo) as first-line (1L) therapy for nonsquamous or squamous metastatic nonesmall cell lung cancer (mNSCLC)

POD1UM-304:瑞他法尼单抗联合铂类化疗(Chemo)作为非鳞状或鳞状转移性非小细胞肺癌(mNSCLC)的一线(1L)治疗的III期研究

2024-12-010
PRE
Pharmacokinetics, safety, and efficacy of an alternative dosing regimen of sasanlimab in participants with advanced NSCLC and other malignancies
2024-09-110
OAAI
Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer

阳光的通俗易懂的总结: 三氟尿苷/替匹拉西和贝伐单抗治疗难治性转移性结直肠癌

2024-07-020
OAAI
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer

阿来替尼治疗切除的ALK阳性非小细胞肺癌

2024-04-1162
PRE
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results
2023-12-076
OAAI
Durvalumab ± Tremelimumab plus Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden
2023-10-068
OAAI